株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

迷走神経刺激装置:パイプライン分析

Vagus Nerve Stimulators - Medical Devices Pipeline Assessment, 2017

発行 GlobalData 商品コード 345364
出版日 ページ情報 英文 97 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.24円で換算しております。
Back to Top
迷走神経刺激装置:パイプライン分析 Vagus Nerve Stimulators - Medical Devices Pipeline Assessment, 2017
出版日: 2017年08月04日 ページ情報: 英文 97 Pages
概要

当レポートでは、世界各国の企業・医療機関などで開発が進められている迷走神経刺激装置のパイプライン製品情報について分析しており、治験と製品開発の進行状況、段階別・セグメント別・国 (地域) 別の動向、企業と製品の詳細情報、最近の製品開発および業界の動向などの情報を盛り込んでいます。

第1章 目次

第2章 イントロダクション

  • 迷走神経刺激装置の概要

第3章 開発中の製品

  • 迷走神経刺激装置 - 開発段階別のパイプライン製品
  • 迷走神経刺激装置 - 国 (地域) 別のパイプライン製品
  • 迷走神経刺激装置 - 規制別のパイプライン製品
  • 迷走神経刺激装置 - 認証時期別 (推定) のパイプライン製品
  • 迷走神経刺激装置 - 現在進行中の治験

第4章 迷走神経刺激装置 - 開発中のパイプライン製品:企業別

  • 迷走神経刺激装置企業 - 開発段階別のパイプライン製品
  • 迷走神経刺激装置 - 開発段階別のパイプライン製品

第5章 迷走神経刺激装置企業と製品の概要

  • BioControl Medical
  • Boston Scientific Corporation
  • CerboMed GmbH
  • Cerebral RX Ltd.
  • Children's Hospital Boston
  • Cyberonics, Inc.
  • DuoCure Ltd.
  • ElectroCore, LLC
  • Medical University of South Carolina
  • MicroTransponder Inc.
  • Neurostream Technologies G.P.
  • Setpoint Medical Corporation
  • Sorin S.p.A.
  • Trifectas Medical Corp.

第6章 迷走神経刺激装置 - 最近の動向

第7章 付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDME0410EPD

GlobalData's Medical Devices sector report, "Vagus Nerve Stimulators - Medical Devices Pipeline Assessment, 2017" provides an overview of Vagus Nerve Stimulators currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Vagus Nerve Stimulators pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Vagus Nerve Stimulators under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Vagus Nerve Stimulators and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Vagus Nerve Stimulators under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 4
  • 1.2 List of Figures 5

2 Introduction 6

  • 2.1 Vagus Nerve Stimulators Overview 6

3 Products under Development 7

  • 3.1 Vagus Nerve Stimulators - Pipeline Products by Stage of Development 7
  • 3.2 Vagus Nerve Stimulators - Pipeline Products by Territory 8
  • 3.3 Vagus Nerve Stimulators - Pipeline Products by Regulatory Path 9
  • 3.4 Vagus Nerve Stimulators - Pipeline Products by Estimated Approval Date 10
  • 3.5 Vagus Nerve Stimulators - Ongoing Clinical Trials 11

4 Vagus Nerve Stimulators - Pipeline Products under Development by Companies 12

  • 4.1 Vagus Nerve Stimulators Companies - Pipeline Products by Stage of Development 12
  • 4.2 Vagus Nerve Stimulators - Pipeline Products by Stage of Development 13

5 Vagus Nerve Stimulators Companies and Product Overview 14

  • 5.1 BioControl Medical Company Overview 14
    • 5.1.1 BioControl Medical Pipeline Products & Ongoing Clinical Trials Overview 14
  • 5.2 Boston Scientific Corp Company Overview 15
    • 5.2.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 15
  • 5.3 CerboMed GmbH Company Overview 19
    • 5.3.1 CerboMed GmbH Pipeline Products & Ongoing Clinical Trials Overview 19
  • 5.4 Cerebral RX Ltd. Company Overview 20
    • 5.4.1 Cerebral RX Ltd. Pipeline Products & Ongoing Clinical Trials Overview 20
  • 5.5 Cyberonics Inc Company Overview 21
    • 5.5.1 Cyberonics Inc Pipeline Products & Ongoing Clinical Trials Overview 21
  • 5.6 DuoCure Ltd. Company Overview 22
    • 5.6.1 DuoCure Ltd. Pipeline Products & Ongoing Clinical Trials Overview 22
  • 5.7 ElectroCore, LLC Company Overview 23
    • 5.7.1 ElectroCore, LLC Pipeline Products & Ongoing Clinical Trials Overview 23
  • 5.8 LivaNova PLC Company Overview 28
    • 5.8.1 LivaNova PLC Pipeline Products & Ongoing Clinical Trials Overview 28
  • 5.9 Medical University of South Carolina Company Overview 36
    • 5.9.1 Medical University of South Carolina Pipeline Products & Ongoing Clinical Trials Overview 36
  • 5.10 MicroTransponder Inc Company Overview 37
    • 5.10.1 MicroTransponder Inc Pipeline Products & Ongoing Clinical Trials Overview 37
  • 5.11 Otto Bock HealthCare GmbH Company Overview 43
    • 5.11.1 Otto Bock HealthCare GmbH Pipeline Products & Ongoing Clinical Trials Overview 43
  • 5.12 Purdue University Company Overview 45
    • 5.12.1 Purdue University Pipeline Products & Ongoing Clinical Trials Overview 45
  • 5.13 Setpoint Medical Corp Company Overview 46
    • 5.13.1 Setpoint Medical Corp Pipeline Products & Ongoing Clinical Trials Overview 46
  • 5.14 Trifectas Medical Corp. Company Overview 50
    • 5.14.1 Trifectas Medical Corp. Pipeline Products & Ongoing Clinical Trials Overview 50

6 Vagus Nerve Stimulators- Recent Developments 51

  • 6.1 Aug 01, 2017: VNS Therapy Receives CE Mark for Expanded MRI Labeling 51
  • 6.2 Jul 31, 2017: SetPoint Medical Appoints Terry Bevirt as VP of Clinical Affairs 51
  • 6.3 Jul 27, 2017: Boston Scientific Announces Results for Second Quarter 2017 52
  • 6.4 Jul 18, 2017: GammaCore, The First Non-Invasive Vagus Nerve Stimulator Applied At The Neck, Now Available For Adult Patients In The U.S. 54
  • 6.5 Jun 29, 2017: FDA Approves VNS Therapy Treatment for Drug-Resistant Epilepsy in Children as Young as Four Years Old 54
  • 6.6 Jun 27, 2017: Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day 56
  • 6.7 Jun 21, 2017: VNS Therapy Receives FDA Approval for Expanded MRI Labeling 58
  • 6.8 Jun 15, 2017: SetPoint Medical Appoints David Chernoff, MD as Chief Medical Officer 58
  • 6.9 Jun 12, 2017: LivaNova Appoints Keyna Skeffington as Senior Vice President and General Counsel 59
  • 6.10 Jun 08, 2017: New Analysis of ACT Clinical Trial Program Highlights Efficacy and Safety of electroCore's gammaCore (non-invasive vagus nerve stimulator) in the Acute Treatment of Episodic Cluster Headache 60
  • 6.11 May 30, 2017: MicroTransponder Presents Long Term Stroke Trial Data at INS and Announces a 120 Patient Pivotal Stroke Trial 61
  • 6.12 May 16, 2017: LivaNova Announces Thad Huston as Chief Financial Officer 61
  • 6.13 May 03, 2017: LivaNova Reports First Quarter 2017 Results 62
  • 6.14 Apr 27, 2017: Boston Scientific Announces Results For First Quarter 2017 63
  • 6.15 Apr 26, 2017: electroCore Announces Data Presentation at the 69th American Academy of Neurology Annual Meeting 64
  • 6.16 Apr 18, 2017: FDA Releases gammaCore, the First Non-Invasive Vagus Nerve Stimulation Therapy Applied at the Neck for Acute Treatment of Pain Associated with Episodic Cluster Headache in Adult Patients 65
  • 6.17 Mar 31, 2017: New Study Finds Promising Treatment Option for Treatment-Resistant Depression 66
  • 6.18 Mar 31, 2017: LivaNova Announces Chief Financial Officer Resignation 67
  • 6.19 Mar 31, 2017: LivaNova Reiterates Full-Year 2017 Guidance 67
  • 6.20 Mar 01, 2017: LivaNova Reports Fourth Quarter and Full-Year 2016 Results 67
  • 6.21 Feb 28, 2017: Results for the second quarter of Fiscal year 2017 - Ergoresearch reports its results for the quarter ended December 31, 2016 70
  • 6.22 Feb 23, 2017: LivaNova Announces Its Intent to Delist from London Stock Exchange 71
  • 6.23 Feb 02, 2017: Boston Scientific Announces Results For Fourth Quarter And Full Year Ended December 31, 2016 71
  • 6.24 Jan 04, 2017: SetPoint Medical Presents Positive Results In Ongoing Crohn's Disease Study 73
  • 6.25 Nov 28, 2016: Results for the first quarter of Fiscal year 2017 - Ergoresearch reports its results for the quarter ended 73
  • 6.26 Nov 28, 2016: Ergoresearch reports its results for the quarter ended September 30, 2016 74
  • 6.27 Nov 14, 2016: Mount Sinai Beth Israel Receive Award from The United States Department of Defense to Study Gulf War Illness with electroCore's non-invasive vagus nerve stimulation therapy 75
  • 6.28 Nov 10, 2016: VNS Therapy is Proven Treatment Option, but Treatment Gap Remains 76
  • 6.29 Nov 02, 2016: LivaNova Announces CEO Transition: Damien McDonald to Succeed Andre-Michel Ballester 77
  • 6.30 Nov 02, 2016: LivaNova Reports Third Quarter 2016 Results 77
  • 6.31 Oct 28, 2016: Results for the fourth quarter and the fiscal year ended June 30, 2016 - Ergoresearch reports its 2016 annual results 79
  • 6.32 Oct 26, 2016: Boston Scientific Announces Results For Third Quarter 2016 79
  • 6.33 Oct 19, 2016: SetPoint Medical Presents Positive Clinical Results in Crohn's Disease 81
  • 6.34 Oct 19, 2016: St. Jude Medical Reports Third Quarter 2016 Results 82
  • 6.35 Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer 83
  • 6.36 Sep 29, 2016: LivaNova Announces Half-Year Financial Report 84

7 Appendix 94

  • 7.1 Methodology 94
  • 7.2 About GlobalData 97
  • 7.3 Contact Us 97
  • 7.4 Disclaimer 97

List of Tables

1.1 List of Tables

  • Table 1: Vagus Nerve Stimulators - Pipeline Products by Stage of Development 7
  • Table 2: Vagus Nerve Stimulators - Pipeline Products by Territory 8
  • Table 3: Vagus Nerve Stimulators - Pipeline Products by Regulatory Path 9
  • Table 4: Vagus Nerve Stimulators - Pipeline Products by Estimated Approval Date 10
  • Table 5: Vagus Nerve Stimulators - Ongoing Clinical Trials 11
  • Table 6: Vagus Nerve Stimulators Companies - Pipeline Products by Stage of Development 12
  • Table 7: Vagus Nerve Stimulators - Pipeline Products by Stage of Development 13
  • Table 8: BioControl Medical Pipeline Products & Ongoing Clinical Trials Overview 14
  • Table 9: CardioFit System - Product Status 14
  • Table 10: CardioFit System - Product Description 14
  • Table 11: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 15
  • Table 12: AMT System - Product Status 15
  • Table 13: AMT System - Product Description 15
  • Table 14: Vagal Nerve Stimulator - Product Status 16
  • Table 15: Vagal Nerve Stimulator - Product Description 16
  • Table 16: Boston Scientific Corp - Ongoing Clinical Trials Overview 17
  • Table 17: Vagal Nerve Stimulator - Neural Cardiac Therapy for Heart Failure Study 18
  • Table 18: CerboMed GmbH Pipeline Products & Ongoing Clinical Trials Overview 19
  • Table 19: t-VNS - Dementia - Product Status 19
  • Table 20: t-VNS - Dementia - Product Description 19
  • Table 21: Cerebral RX Ltd. Pipeline Products & Ongoing Clinical Trials Overview 20
  • Table 22: FitNes System - Alzheimer's Disease - Product Status 20
  • Table 23: FitNes System - Alzheimer's Disease - Product Description 20
  • Table 24: Cyberonics Inc Pipeline Products & Ongoing Clinical Trials Overview 21
  • Table 25: Nerve Wrap - Product Status 21
  • Table 26: Nerve Wrap - Product Description 21
  • Table 27: DuoCure Ltd. Pipeline Products & Ongoing Clinical Trials Overview 22
  • Table 28: Intraluminal Implantable Device - Product Status 22
  • Table 29: Intraluminal Implantable Device - Product Description 22
  • Table 30: ElectroCore, LLC Pipeline Products & Ongoing Clinical Trials Overview 23
  • Table 31: GammaCore - Medication Overuse Headache - Product Status 23
  • Table 32: GammaCore - Medication Overuse Headache - Product Description 23
  • Table 33: GammaCore - Migraine - Product Status 24
  • Table 34: GammaCore - Migraine - Product Description 24
  • Table 35: Resolve Stimulator - Product Status 24
  • Table 36: Resolve Stimulator - Product Description 25
  • Table 37: ElectroCore, LLC - Ongoing Clinical Trials Overview 26
  • Table 38: GammaCore - Migraine - A Prospective, Multi-centre, Randomized, Double-blind, Sham-controlled Study of gammaCore Non-invasive Vagus Nerve Stimulator (nVNS) for the Acute Treatment of Migraine 27
  • Table 39: LivaNova PLC Pipeline Products & Ongoing Clinical Trials Overview 28
  • Table 40: Aspire NP - Product Status 28
  • Table 41: Aspire NP - Product Description 29
  • Table 42: Centro Generator - Product Status 29
  • Table 43: Centro Generator - Product Description 29
  • Table 44: CentroSR Generator - Product Status 30
  • Table 45: CentroSR Generator - Product Description 30
  • Table 46: Equilia - Product Status 30
  • Table 47: Equilia - Product Description 31
  • Table 48: Griffin - Pulse Generator - Product Status 31
  • Table 49: Griffin - Pulse Generator - Product Description 31
  • Table 50: Intense Neuromodulation - Heart Failure - Product Status 32
  • Table 51: Intense Neuromodulation - Heart Failure - Product Description 32
  • Table 52: PhoenixRF SR - Product Status 32
  • Table 53: PhoenixRF SR - Product Description 33
  • Table 54: VITARIA System - Chronic Heart Failure - Product Status 33
  • Table 55: VITARIA System - Chronic Heart Failure - Product Description 33
  • Table 56: LivaNova PLC - Ongoing Clinical Trials Overview 34
  • Table 57: Equilia - Vagal Nerve Stimulation: Safe-guarding Heart Failure Patients (VANGUARD) 35
  • Table 58: Medical University of South Carolina Pipeline Products & Ongoing Clinical Trials Overview 36
  • Table 59: Transcutaneous Auricular Vagus Nerve Stimulator (taVNS) - Product Status 36
  • Table 60: Transcutaneous Auricular Vagus Nerve Stimulator (taVNS) - Product Description 36
  • Table 61: MicroTransponder Inc Pipeline Products & Ongoing Clinical Trials Overview 37
  • Table 62: SAINT System - Anxiety Disorders - Product Status 37
  • Table 63: SAINT System - Anxiety Disorders - Product Description 38
  • Table 64: SAINT System - Tinnitus - Product Status 38
  • Table 65: SAINT System - Tinnitus - Product Description 38
  • Table 66: Serenity System - Tinnitus - Product Status 39
  • Table 67: Serenity System - Tinnitus - Product Description 39
  • Table 68: Vivistim Device - Product Status 39
  • Table 69: Vivistim Device - Product Description 40
  • Table 70: MicroTransponder Inc - Ongoing Clinical Trials Overview 41
  • Table 71: Vivistim Device - A Pivotal Randomized Study Assessing Vagus Nerve Stimulation (VNS) During Rehabilitation for Improved Upper Limb Motor Function after Stroke: VNS-REHAB 42
  • Table 72: Vivistim Device - A Randomized Pilot Study Assessing Vagus Nerve Stimulation (VNS) During Rehabilitation for Improved Upper Limb Motor Function after Stroke (MicroTransponder's Vivistim System) - Study MT-St-02 - Stroke 42
  • Table 73: Otto Bock HealthCare GmbH Pipeline Products & Ongoing Clinical Trials Overview 43
  • Table 74: Neuromodulation Device - Epilepsy - Product Status 43
  • Table 75: Neuromodulation Device - Epilepsy - Product Description 43
  • Table 76: Neuromodulation Device - Sleep Apnea - Product Status 44
  • Table 77: Neuromodulation Device - Sleep Apnea - Product Description 44
  • Table 78: Purdue University Pipeline Products & Ongoing Clinical Trials Overview 45
  • Table 79: Bionode Device - Product Status 45
  • Table 80: Bionode Device - Product Description 45
  • Table 81: Setpoint Medical Corp Pipeline Products & Ongoing Clinical Trials Overview 46
  • Table 82: Implantable Neurostimulation Device - Rheumatoid Arthritis - Product Status 46
  • Table 83: Implantable Neurostimulation Device - Rheumatoid Arthritis - Product Description 46
  • Table 84: SetPoint Immune System Regulator - Crohn's Disease - Product Status 47
  • Table 85: SetPoint Immune System Regulator - Crohn's Disease - Product Description 47
  • Table 86: Setpoint Medical Corp - Ongoing Clinical Trials Overview 48
  • Table 87: SetPoint Immune System Regulator - Crohn's Disease - Study of the Safety and Efficacy of Neurostimulation of the Cholinergic Anti-inflammatory Pathway Using a Vagal Nerve Stimulation Device in Patients with Active Refractory Crohn's Disease 49
  • Table 88: Trifectas Medical Corp. Pipeline Products & Ongoing Clinical Trials Overview 50
  • Table 89: Neurostimulation Device - Stroke Recovery - Product Status 50
  • Table 90: Neurostimulation Device - Stroke Recovery - Product Description 50
  • Table 91: Glossary 96

List of Figures

1.2 List of Figures

  • Figure 1: Vagus Nerve Stimulators - Pipeline Products by Stage of Development 7
  • Figure 2: Vagus Nerve Stimulators - Pipeline Products by Territory 8
  • Figure 3: Vagus Nerve Stimulators - Pipeline Products by Regulatory Path 9
  • Figure 4: Vagus Nerve Stimulators - Pipeline Products by Estimated Approval Date 10
  • Figure 5: Vagus Nerve Stimulators - Ongoing Clinical Trials 11
Back to Top